Cargando…

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

OBJECTIVE: This study evaluated the efficacy and safety of ATL1102, an antisense oligonucleotide that selectively targets the RNA for human CD49d, the α subunit of very late antigen 4, in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In a multicenter, double-blind, placebo-co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Limmroth, Volker, Barkhof, Frederik, Desem, Nuket, Diamond, Mark P., Tachas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240428/ https://www.ncbi.nlm.nih.gov/pubmed/25239835 http://dx.doi.org/10.1212/WNL.0000000000000926

Ejemplares similares

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies
por: Duchartre, Yann, et al.
Publicado: (2017)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Pilot study of a ketogenic diet in relapsing-remitting MS
por: Brenton, J. Nicholas, et al.
Publicado: (2019)

1102. Evaluation of Vancomycin Accumulation in Patients with Obesity
por: Assadoon, Maha, et al.
Publicado: (2021)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
por: Camu, William, et al.
Publicado: (2019)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

ATL internals: working with ATL 8
por: Tavares, Chris
Publicado: (2006)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS
por: Sriram, Subramaniam, et al.
Publicado: (2018)

ATL internals
por: Rector, Brent, et al.
Publicado: (1999)

ATL internals /
por: Rector, Brent
Publicado: (1999)

Dr. Atl /
por: Luna Arroyo, Antonio
Publicado: (1992)

Redox Imbalance in CD4+ T Cells of Relapsing-Remitting Multiple Sclerosis Patients
por: Tavassolifar, Mohammad Javad, et al.
Publicado: (2020)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients
por: Álvarez-Sánchez, Nuria, et al.
Publicado: (2019)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

OA11.02. A model of integrative care for low back pain
por: Eisenberg, D, et al.
Publicado: (2012)

1102. Ertapenem vs. Nonertapenem Antibiotics in Colorectal Surgery: A Stewardship Opportunity
por: LaDow, Tiffany, et al.
Publicado: (2019)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Can we cure ATL: new drugs and targeting ATL stem cells
por: Hermine, Olivier
Publicado: (2014)

Dr. Atl : pinturas y dibujos /
por: Atl, Dr., 1875-1964
Publicado: (1974)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS
por: Stellmann, Jan‐Patrick, et al.
Publicado: (2016)

Investigating the relationship between multi-scale perfusion and white matter microstructural integrity in patients with relapsing-remitting MS
por: Sisco, Nicholas J, et al.
Publicado: (2021)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
por: Kearns, Patrick K A, et al.
Publicado: (2022)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m1m9qvbnub8liua53a8p907plb